vs

Side-by-side financial comparison of Kenvue (KVUE) and QVC Group, Inc. (QVCGA). Click either name above to swap in a different company.

Kenvue is the larger business by last-quarter revenue ($3.8B vs $2.7B, roughly 1.4× QVC Group, Inc.). Kenvue runs the higher net margin — 8.7% vs -1.4%, a 10.1% gap on every dollar of revenue. On growth, Kenvue posted the faster year-over-year revenue change (3.2% vs -9.1%). Kenvue produced more free cash flow last quarter ($744.0M vs $191.0M). Over the past eight quarters, QVC Group, Inc.'s revenue compounded faster (6.9% CAGR vs -1.5%).

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.

QVC Group, is an American media conglomerate controlled by company chairman John C. Malone, who owns a majority of the voting shares.

KVUE vs QVCGA — Head-to-Head

Bigger by revenue
KVUE
KVUE
1.4× larger
KVUE
$3.8B
$2.7B
QVCGA
Growing faster (revenue YoY)
KVUE
KVUE
+12.3% gap
KVUE
3.2%
-9.1%
QVCGA
Higher net margin
KVUE
KVUE
10.1% more per $
KVUE
8.7%
-1.4%
QVCGA
More free cash flow
KVUE
KVUE
$553.0M more FCF
KVUE
$744.0M
$191.0M
QVCGA
Faster 2-yr revenue CAGR
QVCGA
QVCGA
Annualised
QVCGA
6.9%
-1.5%
KVUE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KVUE
KVUE
QVCGA
QVCGA
Revenue
$3.8B
$2.7B
Net Profit
$330.0M
$-37.0M
Gross Margin
56.5%
32.9%
Operating Margin
14.2%
3.7%
Net Margin
8.7%
-1.4%
Revenue YoY
3.2%
-9.1%
Net Profit YoY
12.6%
97.1%
EPS (diluted)
$0.16
$-17.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$3.8B
$2.7B
Q3 25
$3.8B
$2.2B
Q2 25
$3.8B
$2.2B
Q1 25
$3.7B
$2.1B
Q4 24
$3.7B
$2.9B
Q3 24
$3.9B
$2.3B
Q2 24
$4.0B
$2.4B
Q1 24
$3.9B
$2.3B
Net Profit
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$330.0M
$-37.0M
Q3 25
$398.0M
$-80.0M
Q2 25
$420.0M
$-2.2B
Q1 25
$322.0M
$-100.0M
Q4 24
$293.0M
$-1.3B
Q3 24
$383.0M
$-23.0M
Q2 24
$58.0M
$20.0M
Q1 24
$296.0M
$-1.0M
Gross Margin
KVUE
KVUE
QVCGA
QVCGA
Q4 25
56.5%
32.9%
Q3 25
59.1%
34.0%
Q2 25
58.9%
36.4%
Q1 25
58.0%
34.2%
Q4 24
56.5%
33.3%
Q3 24
58.5%
35.3%
Q2 24
59.1%
36.4%
Q1 24
57.6%
35.5%
Operating Margin
KVUE
KVUE
QVCGA
QVCGA
Q4 25
14.2%
3.7%
Q3 25
16.7%
2.7%
Q2 25
18.0%
-101.6%
Q1 25
14.9%
0.7%
Q4 24
13.2%
-43.2%
Q3 24
16.8%
6.5%
Q2 24
3.9%
6.9%
Q1 24
14.1%
6.2%
Net Margin
KVUE
KVUE
QVCGA
QVCGA
Q4 25
8.7%
-1.4%
Q3 25
10.6%
-3.6%
Q2 25
10.9%
-99.4%
Q1 25
8.6%
-4.8%
Q4 24
8.0%
-43.7%
Q3 24
9.8%
-1.0%
Q2 24
1.5%
0.8%
Q1 24
7.6%
-0.0%
EPS (diluted)
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$0.16
$-17.37
Q3 25
$0.21
$-9.89
Q2 25
$0.22
$-275.46
Q1 25
$0.17
$-0.25
Q4 24
$0.16
Q3 24
$0.20
$-0.06
Q2 24
$0.03
$2.57
Q1 24
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KVUE
KVUE
QVCGA
QVCGA
Cash + ST InvestmentsLiquidity on hand
$1.1B
$2.0B
Total DebtLower is stronger
$790.0M
Stockholders' EquityBook value
$10.8B
$-3.1B
Total Assets
$27.1B
$7.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$1.1B
$2.0B
Q3 25
$1.1B
$1.8B
Q2 25
$1.1B
$897.0M
Q1 25
$1.1B
$833.0M
Q4 24
$1.1B
$905.0M
Q3 24
$1.1B
$873.0M
Q2 24
$1.0B
$1.2B
Q1 24
$1.2B
$1.1B
Total Debt
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$790.0M
Q3 25
$5.9B
Q2 25
$4.9B
Q1 25
$5.0B
Q4 24
$4.1B
Q3 24
$5.1B
Q2 24
$5.3B
Q1 24
$5.5B
Stockholders' Equity
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$10.8B
$-3.1B
Q3 25
$10.6B
$-3.1B
Q2 25
$10.7B
$-3.0B
Q1 25
$10.1B
$-981.0M
Q4 24
$9.7B
$-971.0M
Q3 24
$10.6B
$397.0M
Q2 24
$10.2B
$328.0M
Q1 24
$10.6B
$255.0M
Total Assets
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$27.1B
$7.6B
Q3 25
$27.2B
$7.6B
Q2 25
$27.1B
$6.7B
Q1 25
$26.3B
$9.0B
Q4 24
$25.6B
$9.2B
Q3 24
$26.9B
$10.8B
Q2 24
$26.4B
$10.9B
Q1 24
$27.3B
$11.0B
Debt / Equity
KVUE
KVUE
QVCGA
QVCGA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
12.74×
Q2 24
16.28×
Q1 24
21.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KVUE
KVUE
QVCGA
QVCGA
Operating Cash FlowLast quarter
$854.0M
$244.0M
Free Cash FlowOCF − Capex
$744.0M
$191.0M
FCF MarginFCF / Revenue
19.7%
7.1%
Capex IntensityCapex / Revenue
2.9%
2.0%
Cash ConversionOCF / Net Profit
2.59×
TTM Free Cash FlowTrailing 4 quarters
$1.7B
$118.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$854.0M
$244.0M
Q3 25
$294.0M
$4.0M
Q2 25
$621.0M
$86.0M
Q1 25
$428.0M
$-60.0M
Q4 24
$793.0M
$212.0M
Q3 24
$249.0M
$20.0M
Q2 24
$440.0M
$267.0M
Q1 24
$287.0M
$26.0M
Free Cash Flow
KVUE
KVUE
QVCGA
QVCGA
Q4 25
$744.0M
$191.0M
Q3 25
$196.0M
$-27.0M
Q2 25
$533.0M
$48.0M
Q1 25
$249.0M
$-94.0M
Q4 24
$661.0M
$150.0M
Q3 24
$190.0M
$-23.0M
Q2 24
$350.0M
$213.0M
Q1 24
$134.0M
$-14.0M
FCF Margin
KVUE
KVUE
QVCGA
QVCGA
Q4 25
19.7%
7.1%
Q3 25
5.2%
-1.2%
Q2 25
13.9%
2.1%
Q1 25
6.7%
-4.5%
Q4 24
18.1%
5.1%
Q3 24
4.9%
-1.0%
Q2 24
8.8%
8.8%
Q1 24
3.4%
-0.6%
Capex Intensity
KVUE
KVUE
QVCGA
QVCGA
Q4 25
2.9%
2.0%
Q3 25
2.6%
1.4%
Q2 25
2.3%
1.7%
Q1 25
4.8%
1.6%
Q4 24
3.6%
2.1%
Q3 24
1.5%
1.8%
Q2 24
2.3%
2.2%
Q1 24
3.9%
1.7%
Cash Conversion
KVUE
KVUE
QVCGA
QVCGA
Q4 25
2.59×
Q3 25
0.74×
Q2 25
1.48×
Q1 25
1.33×
Q4 24
2.71×
Q3 24
0.65×
Q2 24
7.59×
13.35×
Q1 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KVUE
KVUE

Self Care$1.6B42%
Essential Health$1.1B30%
Skin Health And Beauty$1.0B28%

QVCGA
QVCGA

Other$915.0M34%
Home$754.0M28%
Beauty$260.0M10%
Apparel$254.0M9%
Electronics$187.0M7%
Accessories$181.0M7%
Jewelry$87.0M3%
Manufactured Product Other$38.0M1%

Related Comparisons